Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...
New long-term clinical data for BioNTech's personalized mRNA cancer vaccine has delivered a potentially paradigm-shifting result in one of oncology's most challenging diseases. Presented at the ...
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...
A landmark six-year survival milestone for a personalized cancer vaccine has provided a powerful boost to BioNTech SE as it navigates a critical strategic and financial transition. New data from a ...
BioNTech SE (NASDAQ:BNTX) has been notified by its partner, OncoC4 Inc., that the FDA has imposed a partial clinical hold on its Phase 3 PRESERVE-003 trial. The open-label, randomized study evaluates ...
By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated ...
Biontech Se Sponsored Adr ((BNTX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
BioNTech rallies 22% as long-term data shows mRNA vaccine BNT122 extends survival in pancreatic cancer; company targets 15 Phase 3 trials by 2026 with €17B cash reserve.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results